Abstract: Bivalent antibody constructs comprising (a) a first polypeptide chain comprising a VL sequence, a CH3 sequence, a CH2 sequence, and a CH3 sequence, arranged from N- to C-terminus in a VL-CH3-CH2-CH3 orientation; (b) a second polypeptide chain comprising a VH sequence and a CH3 sequence, arranged from N- to C-terminus in a VH-CH3 orientation; (c) a third polypeptide chain comprising a VL sequence, a CL sequence, an antibody CH2 sequence, and a CH3 sequence, arranged from N- to C-terminus in a VL-CL-CH2-CH3 orientation; (d) a fourth polypeptide chain comprising a VH sequence and a CH1 sequence, arranged from N- to C-terminus in a VH-CH1 orientation; wherein the amino acid sequences of the C-terminal CH3 domains in the first and third polypeptide chains are different from one another and comprise complementary knob-in-hole mutations, and pharmaceutical compositions comprising the antibody constructs, and methods of use thereof are provided.

Abstract: The present disclosure provides multispecific binding agents (e.g., antibodies, such as bispecific antibodies) that have a first binding domain that binds to CD47, including human CD47, and one or more additional binding domains that bind to one or more targets that are not CD47, such as PD-L1 and uses thereof.

Abstract: The present disclosure provides CD47 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and uses thereof.

Abstract: The present disclosure provides PD-L1 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and uses thereof.

Abstract: Multispecific Treg-binding molecules, constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

Abstract: Multispecific Treg-binding molecules, constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

Abstract: Multivalent receptor-clustering agonist antibody constructs are provided. The constructs are capable of (i) binding a cell surface receptor target that requires clustering for agonist activity, and (ii) clustering the receptor target on the cell surface in the absence of an independent cross-linking agent. Each of the target receptor-binding antigen binding sites of the construct is contributed by antibody variable region binding domains. Also provided are pharmaceutical compositions comprising the antibody construct, and methods of treating diseases, notably cancer, by administering therapeutically effective amounts of the pharmaceutical composition.

Abstract: Trispecific trivalent antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

Abstract: Binding molecules, constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

Abstract: Anti-ROR antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

Abstract: Multivalent antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

Abstract: Methods for screening libraries of polypeptides for biologically activity on cells. For example, polypeptides can be synthesized and encapsulated along with their coding sequences in microcapsules of an emulsion. Emulsion microcapsules can then be fused with microcapsules comprising test cells and biological activity on the cells is assessed to identify biologically active polypeptides and nucleic acid molecules encoding the same.

Abstract: Methods for screening libraries of polypeptides for biologically activity on cells. For example, polypeptides can be synthesized and encapsulated along with their coding sequences in microcapsules of an emulsion. Emulsion microcapsules can then be fused with microcapsules comprising test cells and biological activity on the cells is assessed to identify biologically active polypeptides and nucleic acid molecules encoding the same.

Abstract: An aminocoumarin conjugated to a fluorescent label through a secondary amine, is operative as a fluorescent polarization probe of the DNA gyrase B or topoisomerase IV E subunit. The probe is used for detecting topoisomerase inhibitor binding by fluorescence polarization, particularly in a high-through put topoisomerase inhibitor assay.

Abstract: An aminocoumarin conjugated to a fluorescent label through a secondary amine, is operative as a fluorescent polarization probe of the DNA gyrase B or topoisomerase IV E subunit. The probe is used for detecting topoisomerase inhibitor binding by fluorescence polarization, particularly in a high-through put topoisomerase inhibitor assay.